Bosh sahifaMOLN • NASDAQ
add
Molecular Partners AG
Yopilish kursi
3,75 $
Kunlik diapazon
3,72 $ - 3,74 $
Yillik diapazon
3,36 $ - 7,60 $
Bozor kapitalizatsiyasi
144,10 mln USD
Oʻrtacha hajm
3,66 ming
Narx/foyda
-
Dividend daromadliligi
-
Bozor yangiliklari
Moliyaviy axborot
Moliyaviy hisobot
Daromad
Sof foyda
| (CHF) | iyn, 2025info | Y/Y qiyosi |
|---|---|---|
Daromad | — | — |
Joriy xarajat | 3,99 mln | -10,05% |
Sof foyda | -20,40 mln | -35,25% |
Sof foyda marjasi | — | — |
Har bir ulushga tushum | -0,56 | — |
EBITDA | -14,15 mln | 7,98% |
Amaldagi soliq stavkasi | — | — |
Balans
Jami aktivlari
Jami passivlari
| (CHF) | iyn, 2025info | Y/Y qiyosi |
|---|---|---|
Naqd pul va qisqa investitsiyalar | 114,49 mln | -28,05% |
Jami aktivlari | 124,25 mln | -27,17% |
Jami passivlari | 17,59 mln | 16,89% |
Umumiy kapital | 106,66 mln | — |
Tarqatilgan aksiyalar | 37,39 mln | — |
Narxi/balansdagi bahosi | 1,32 | — |
Aktivlardan daromad | -27,70% | — |
Kapitaldan daromad | -30,77% | — |
Pul aylanmasi
Naqd pulning sof oʻzgarishi
| (CHF) | iyn, 2025info | Y/Y qiyosi |
|---|---|---|
Sof foyda | -20,40 mln | -35,25% |
Operatsiyalardan naqd pul | -13,10 mln | 16,68% |
Sarmoyadan naqd pul | 14,97 mln | 13,85% |
Moliyadan naqd pul | -243,00 ming | 8,99% |
Naqd pulning sof oʻzgarishi | 603,00 ming | 122,68% |
Boʻsh pul | -3,61 mln | 63,16% |
Haqida
Molecular Partners AG is a clinical-stage biopharmaceutical company based in Zürich, Switzerland. The company is developing a new class of potent, specific and versatile small-protein therapies called DARPins, with potential clinical applications in a range of disease areas including oncology, immuno-oncology, ophthalmology, and infectious diseases. Molecular Partners currently has two DARPin molecules in clinical development, and a broad pipeline of molecules in preclinical development. Wikipedia
Tashkil etilgan
2004
Xodimlar soni
153
